Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 94
Filter
1.
Viruses ; 11(8)2019 07 27.
Article in English | MEDLINE | ID: mdl-31357656

ABSTRACT

The feline immunodeficiency virus (FIV) full-length Pr50Gag precursor is a key player in the assembly of new viral particles. It is also a critical component of the efficient selection and packaging of two copies of genomic RNA (gRNA) into the newly formed virus particles from a wide pool of cellular and spliced viral RNA. To understand the molecular mechanisms involved during FIV gRNA packaging, we expressed the His6-tagged and untagged recombinant FIV Pr50Gag protein both in eukaryotic and prokaryotic cells. The recombinant Pr50Gag-His6-tag fusion protein was purified from soluble fractions of prokaryotic cultures using immobilized metal affinity chromatography (IMAC). This purified protein was able to assemble in vitro into virus-like particles (VLPs), indicating that it preserved its ability to oligomerize/multimerize. Furthermore, VLPs formed in eukaryotic cells by the FIV full-length Pr50Gag both in the presence and absence of His6-tag could package FIV sub-genomic RNA to similar levels, suggesting that the biological activity of the recombinant full-length Pr50Gag fusion protein was retained in the presence of His6-tag at the carboxy terminus. Successful expression and purification of a biologically active, recombinant full-length Pr50Gag-His6-tag fusion protein will allow study of the intricate RNA-protein interactions involved during FIV gRNA encapsidation.


Subject(s)
Gene Products, gag/genetics , Immunodeficiency Virus, Feline/genetics , Virus Assembly , Animals , Cats , Escherichia coli/genetics , Gene Expression , Gene Products, gag/isolation & purification , Genome, Viral , HEK293 Cells , Humans , RNA, Viral/genetics , Recombinant Proteins/genetics
2.
Sci Rep ; 8(1): 11793, 2018 08 07.
Article in English | MEDLINE | ID: mdl-30087395

ABSTRACT

MPMV precursor polypeptide Pr78Gag orchestrates assembly and packaging of genomic RNA (gRNA) into virus particles. Therefore, we have expressed recombinant full-length Pr78Gag either with or without His6-tag in bacterial as well as eukaryotic cultures and purified the recombinant protein from soluble fractions of the bacterial cultures. The recombinant Pr78Gag protein has the intrinsic ability to assemble in vitro to form virus like particles (VLPs). Consistent with this observation, the recombinant protein could form VLPs in both prokaryotes and eukaryotes. VLPs formed in eukaryotic cells by recombinant Pr78Gag with or without His6-tag can encapsidate MPMV transfer vector RNA, suggesting that the inclusion of the His6-tag to the full-length Pr78Gag did not interfere with its expression or biological function. This study demonstrates the expression and purification of a biologically active, recombinant Pr78Gag, which should pave the way to study RNA-protein interactions involved in the MPMV gRNA packaging process.


Subject(s)
Gene Expression , Gene Products, gag/chemistry , Gene Products, gag/isolation & purification , Mason-Pfizer monkey virus/chemistry , Gene Products, gag/biosynthesis , Gene Products, gag/genetics , HEK293 Cells , Humans , Mason-Pfizer monkey virus/genetics , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification
3.
Viruses ; 10(6)2018 06 18.
Article in English | MEDLINE | ID: mdl-29912170

ABSTRACT

The mouse mammary tumor virus (MMTV) Pr77Gag polypeptide is an essential retroviral structural protein without which infectious viral particles cannot be formed. This process requires specific recognition and packaging of dimerized genomic RNA (gRNA) by Gag during virus assembly. Most of the previous work on retroviral assembly has used either the nucleocapsid portion of Gag, or other truncated Gag derivatives­not the natural substrate for virus assembly. In order to understand the molecular mechanism of MMTV gRNA packaging process, we expressed and purified full-length recombinant Pr77Gag-His6-tag fusion protein from soluble fractions of bacterial cultures. We show that the purified Pr77Gag-His6-tag protein retained the ability to assemble virus-like particles (VLPs) in vitro with morphologically similar immature intracellular particles. The recombinant proteins (with and without His6-tag) could both be expressed in prokaryotic and eukaryotic cells and had the ability to form VLPs in vivo. Most importantly, the recombinant Pr77Gag-His6-tag fusion proteins capable of making VLPs in eukaryotic cells were competent for packaging sub-genomic MMTV RNAs. The successful expression and purification of a biologically active, full-length MMTV Pr77Gag should lay down the foundation towards performing RNA­protein interaction(s), especially for structure-function studies and towards understanding molecular intricacies during MMTV gRNA packaging and assembly processes.


Subject(s)
Gene Products, gag/metabolism , Mammary Tumor Virus, Mouse/physiology , RNA, Viral/metabolism , Virus Assembly , Escherichia coli/genetics , Gene Expression , Gene Products, gag/genetics , Gene Products, gag/isolation & purification , HEK293 Cells , Humans , Mammary Tumor Virus, Mouse/genetics , Protein Binding , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Virosomes/metabolism
4.
J Sep Sci ; 40(4): 979-990, 2017 02.
Article in English | MEDLINE | ID: mdl-27928907

ABSTRACT

The downstream processing of enveloped virus-like particles is very challenging because of the biophysical and structural similarity between correctly assembled particles and contaminating vesicular particles present in the feedstock. We used hydroxyl-functionalized polymethacrylate monoliths, providing hydrophobic and electrostatic binding contributions, for the purification of HIV-1 gag virus-like particles. The clarified culture supernatant was conditioned with ammonium sulfate and after membrane filtration loaded onto a 1 mL monolith. The binding capacity was 2 × 1012 /mL monolith and was only limited by the pressure drop. By applying either a linear or a step gradient elution, to decrease the ammonium sulfate concentration, the majority of double-stranded DNA (88-90%) and host cell protein impurities (39-61%) could be removed while the particles could be separated into two fractions. Proteomic analysis and evaluation of the p24 concentration showed that one fraction contained majority of the HIV-1 gag and the other fraction was less contaminated with proteins originated from intracellular compartments. We were able to process up to 92 bed volumes of conditioned loading material within 3 h and eluted in average 7.3 × 1011 particles per particle fraction, which is equivalent to 730 vaccination doses of 1 × 109 particles.


Subject(s)
Chemistry Techniques, Analytical/methods , Gene Products, gag/isolation & purification , HIV-1/isolation & purification , Cells, Cultured , Gene Products, gag/metabolism , Humans , Hydrophobic and Hydrophilic Interactions , Hydroxyl Radical/metabolism , Proteomics , Vaccines, Virus-Like Particle/isolation & purification
5.
Genet Mol Res ; 14(4): 14379-86, 2015 Nov 19.
Article in English | MEDLINE | ID: mdl-26600497

ABSTRACT

Endogenous retroviruses are regarded as ideal genetic markers for evolutionary analyses. Birds were some of the initial vertebrates found to contain endogenous retroviruses. However, few studies have investigated the presence and distribution of endogenous retroviruses in goose. In this study, we detected the avian sarcoma and leukosis virus gag gene in the genomic DNA of 8 Chinese native breeds using polymerase chain reaction method. The results indicated that a 1.2-kb avian sarcoma and leukosis virus gag sequence was integrated into all 8 goose breeds. The mean genetic pairwise distance was 0.918% among the investigated geese. To the best of our knowledge, this is the first report demonstrating the presence of the endogenous retroviruses in the domestic goose genome. The genetic structure should be further examined in the domestic goose.


Subject(s)
Alpharetrovirus/genetics , Anseriformes/genetics , Evolution, Molecular , Gene Products, gag/genetics , Animals , Anseriformes/virology , Breeding , DNA, Mitochondrial/genetics , Gene Products, gag/isolation & purification , Genome
6.
J Virol ; 89(20): 10371-82, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26246573

ABSTRACT

UNLABELLED: Previously, no retroviral Gag protein has been highly purified in milligram quantities and in a biologically relevant and active form. We have purified Rous sarcoma virus (RSV) Gag protein and in parallel several truncation mutants of Gag and have studied their biophysical properties and membrane interactions in vitro. RSV Gag is unusual in that it is not naturally myristoylated. From its ability to assemble into virus-like particles in vitro, we infer that RSV Gag is biologically active. By size exclusion chromatography and small-angle X-ray scattering, Gag in solution appears extended and flexible, in contrast to previous reports on unmyristoylated HIV-1 Gag, which is compact. However, by neutron reflectometry measurements of RSV Gag bound to a supported bilayer, the protein appears to adopt a more compact, folded-over conformation. At physiological ionic strength, purified Gag binds strongly to liposomes containing acidic lipids. This interaction is stimulated by physiological levels of phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] and by cholesterol. However, unlike HIV-1 Gag, RSV Gag shows no sensitivity to acyl chain saturation. In contrast with full-length RSV Gag, the purified MA domain of Gag binds to liposomes only weakly. Similarly, both an N-terminally truncated version of Gag that is missing the MA domain and a C-terminally truncated version that is missing the NC domain bind only weakly. These results imply that NC contributes to membrane interaction in vitro, either by directly contacting acidic lipids or by promoting Gag multimerization. IMPORTANCE: Retroviruses like HIV assemble at and bud from the plasma membrane of cells. Assembly requires the interaction between thousands of Gag molecules to form a lattice. Previous work indicated that lattice formation at the plasma membrane is influenced by the conformation of monomeric HIV. We have extended this work to the more tractable RSV Gag. Our results show that RSV Gag is highly flexible and can adopt a folded-over conformation on a lipid bilayer, implicating both the N and C termini in membrane binding. In addition, binding of Gag to membranes is diminished when either terminal domain is truncated. RSV Gag membrane association is significantly less sensitive than HIV Gag membrane association to lipid acyl chain saturation. These findings shed light on Gag assembly and membrane binding, critical steps in the viral life cycle and an untapped target for antiretroviral drugs.


Subject(s)
Cell Membrane/chemistry , Gene Products, gag/chemistry , Lipid Bilayers/chemistry , Rous sarcoma virus/chemistry , Virion/chemistry , Cholesterol/chemistry , Escherichia coli/genetics , Escherichia coli/metabolism , Gene Expression , Gene Products, gag/genetics , Gene Products, gag/isolation & purification , HIV-1/chemistry , Hydrodynamics , Osmolar Concentration , Phosphatidylcholines/chemistry , Phosphatidylethanolamines/chemistry , Phosphatidylinositol 4,5-Diphosphate/chemistry , Protein Binding , Protein Folding , Protein Structure, Secondary , Protein Structure, Tertiary , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Rous sarcoma virus/ultrastructure , Virion/ultrastructure
7.
PLoS One ; 8(2): e56424, 2013.
Article in English | MEDLINE | ID: mdl-23457565

ABSTRACT

The Feline Immunodeficiency Virus (FIV) capsid protein p24 oligomerizes to form a closed capsid that protects the viral genome. Because of its crucial role in the virion, FIV p24 is an interesting target for the development of therapeutic strategies, although little is known about its structure and assembly. We defined and optimized a protocol to overexpress recombinant FIV capsid protein in a bacterial system. Circular dichroism and isothermal titration calorimetry experiments showed that the structure of the purified FIV p24 protein was comprised mainly of α-helices. Dynamic light scattering (DLS) and cross-linking experiments demonstrated that p24 was monomeric at low concentration and dimeric at high concentration. We developed a protocol for the in vitro assembly of the FIV capsid. As with HIV, an increased ionic strength resulted in FIV p24 assembly in vitro. Assembly appeared to be dependent on temperature, salt concentration, and protein concentration. The FIV p24 assembly kinetics was monitored by DLS. A limit end-point diameter suggested assembly into objects of definite shapes. This was confirmed by electron microscopy, where FIV p24 assembled into spherical particles. Comparison of FIV p24 with other retroviral capsid proteins showed that FIV assembly is particular and requires further specific study.


Subject(s)
Biophysical Phenomena , Capsid/metabolism , Gene Products, gag/chemistry , Gene Products, gag/metabolism , Immunodeficiency Virus, Feline/metabolism , Capsid/drug effects , Gene Products, gag/genetics , Gene Products, gag/isolation & purification , Protein Conformation/drug effects , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Salts/pharmacology , Temperature
8.
Protein Expr Purif ; 80(2): 176-84, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21871964

ABSTRACT

Diagnosis of infectious diseases often requires demonstration of antibodies to the microbe (serology). A large set of antigens, covering viruses, bacteria, fungi and parasites may be needed. Recombinant proteins have a prime role in serological tests. Suspension arrays offer high throughput for simultaneous measurement of many different antibodies. We here describe a rational process for preparation, purification and coupling to beads of recombinant proteins prepared in Escherichia coli derivate Origami B, to be used in a serological Luminex suspension array. All six Gag and Env proteins (p10, p12, p15, p30, gp70 and p15E), from the xenotropic murine leukemia virus-related virus (XMRV), were prepared, allowing the creation of a multiepitope XMRV antibody assay. The procedure is generic and allows production of protein antigens ready for serological testing in a few working days. Instability and aggregation problems were circumvented by expression of viral proteins fused to a carrier protein (thioredoxin A; TrxA), purification via inclusion body formation, urea solubilization, His tag affinity chromatography and direct covalent coupling to microspheres without removal of the elution buffer. The yield of one preparation (2-10mg fusion protein per 100ml culture) was enough for 20-100 coupling reactions, sufficing for tests of many tens of thousands of sera. False serological positivity due to antibodies binding to TrxA and to traces of E. coli proteins remaining in the preparation could be reduced by preabsorption of sera with free TrxA and E. coli extract. The recombinant antigens were evaluated using anti-XMRV antibodies. Although hybrid proteins expressed in E. coli in this way will not have the entire tertiary structure and posttranslational modifications of the native proteins, they contain a large subset of the epitopes associated with them. The described strategy is simple, quick, efficient and cheap. It should be applicable for suspension array serology in general.


Subject(s)
Gene Products, env/metabolism , Gene Products, gag/metabolism , Recombinant Fusion Proteins/isolation & purification , Xenotropic murine leukemia virus-related virus/immunology , Amino Acid Sequence , Animals , Antibodies, Viral/immunology , Antibody Specificity , Antigens, Viral/genetics , Antigens, Viral/immunology , Antigens, Viral/isolation & purification , Antigens, Viral/metabolism , Carrier Proteins/genetics , Carrier Proteins/metabolism , Cloning, Molecular , Cytoplasm/genetics , Cytoplasm/metabolism , Electrophoresis, Polyacrylamide Gel , Escherichia coli/genetics , Escherichia coli/metabolism , Escherichia coli Proteins/genetics , Escherichia coli Proteins/metabolism , Gene Products, env/genetics , Gene Products, env/immunology , Gene Products, env/isolation & purification , Gene Products, gag/genetics , Gene Products, gag/immunology , Gene Products, gag/isolation & purification , Genetic Vectors/genetics , Genetic Vectors/metabolism , Humans , Immune Sera/immunology , Inclusion Bodies/metabolism , Molecular Sequence Data , Plasmids/genetics , Plasmids/metabolism , Protein Denaturation , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , Recombinant Fusion Proteins/metabolism , Serologic Tests , Solubility , Thioredoxins/genetics , Thioredoxins/metabolism
9.
Retrovirology ; 8: 30, 2011 May 09.
Article in English | MEDLINE | ID: mdl-21554716

ABSTRACT

BACKGROUND: The human genome harbors several largely preserved HERV-K(HML-2) elements. Although this retroviral family comes closest of all known HERVs to producing replication competent virions, mutations acquired during their chromosomal residence have rendered them incapable of expressing infectious particles. This also holds true for the HERV-K113 element that has conserved open reading frames (ORFs) for all its proteins in addition to a functional LTR promoter. Uncertainty concerning the localization and impact of post-insertional mutations has greatly hampered the functional characterization of these ancient retroviruses and their proteins. However, analogous to other betaretroviruses, it is known that HERV-K(HML-2) virions undergo a maturation process during or shortly after release from the host cell. During this process, the subdomains of the Gag polyproteins are released by proteolytic cleavage, although the nature of the mature HERV-K(HML-2) Gag proteins and the exact position of the cleavage sites have until now remained unknown. RESULTS: By aligning the amino acid sequences encoded by the gag-pro-pol ORFs of HERV-K113 with the corresponding segments from 10 other well-preserved human specific elements we identified non-synonymous post-insertional mutations that have occurred in this region of the provirus. Reversion of these mutations and a partial codon optimization facilitated the large-scale production of maturation-competent HERV-K113 virus-like particles (VLPs). The Gag subdomains of purified mature VLPs were separated by reversed-phase high-pressure liquid chromatography and initially characterized using specific antibodies. Cleavage sites were identified by mass spectrometry and N-terminal sequencing and confirmed by mutagenesis. Our results indicate that the gag gene product Pr74Gag of HERV-K(HML-2) is processed to yield p15-MA (matrix), SP1 (spacer peptide of 14 amino acids), p15, p27-CA (capsid), p10-NC (nucleocapsid) and two C-terminally encoded glutamine- and proline-rich peptides, QP1 and QP2, spanning 23 and 19 amino acids, respectively. CONCLUSIONS: Expression of reconstituted sequences of original HERV elements is an important tool for studying fundamental aspects of the biology of these ancient viruses. The analysis of HERV-K(HML-2) Gag processing and the nature of the mature Gag proteins presented here will facilitate further studies of the discrete functions of these proteins and of their potential impact on the human host.


Subject(s)
Endogenous Retroviruses/genetics , Gene Products, gag/genetics , Gene Products, gag/metabolism , Peptide Hydrolases/metabolism , Amino Acid Sequence , Chromatography, High Pressure Liquid , Gene Products, gag/isolation & purification , Humans , Mass Spectrometry , Molecular Sequence Data , Sequence Alignment , Virosomes/genetics , Virosomes/isolation & purification , Virosomes/metabolism
10.
Virol Sin ; 25(2): 115-22, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20960308

ABSTRACT

Viruses (e.g. Human immunodeficiency virus, Human simplex virus and Prototype foamy virus) are obligate intracellular parasites and therefore depend on the cellular machinery for cellular trafficking. Bovine foamy virus (BFV) is a member of the Spumaretrovirinae subfamily of Retroviruses, however, details of its cellular trafficking remain unknown. In this study, we cloned the BFV gag gene into prokaryotic expression vector pET28a and purified the denaturalized Gag protein. The protein was used to immunize BALB/c mouse to produce antiserum, which could specifically recognize the BFV Gag protein in BFV-infected cells through western blot assay. Additionally, these results demonstrated that both the optimal and suboptimal cleavage of Gag protein occur in BFV-infected cells. Subsequently, the Gag antiserum was used to investigate subcellular localization of BFV. In immunofluorescence microscopy assays, colocalization microtubules (MTs) and assembling viral particles were clearly observed, which implied that BFV may transport along cellular MTs in host cells. Furthermore, MTs-depolymerizing assay indicated MTs were required for the efficient replication of BFV. In conclusion, our study suggests that BFV has evolved the mechanism to hijack the cellular cytoskeleton for its replication.


Subject(s)
Antibodies, Viral , Gene Products, gag/immunology , Spumavirus/physiology , Virus Replication , Animals , Antibodies, Viral/isolation & purification , Cattle , Cells, Cultured , Cloning, Molecular , Fluorescent Antibody Technique, Direct , Gene Expression , Gene Products, gag/genetics , Gene Products, gag/isolation & purification , Mice , Mice, Inbred BALB C , Microtubules/virology , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Recombinant Proteins/isolation & purification
11.
Pak J Biol Sci ; 11(20): 2433-7, 2008 Oct 15.
Article in English | MEDLINE | ID: mdl-19137855

ABSTRACT

Bovine leukemia virus (BLV) is a member of the family Retroviridae, genus Deltaretrovirus that has three important gene including gag, pol and env. This virus causes B-cell lymphocytosis and lymphosarcoma in cows. In the first step PCR product of gag gene of BLV isolated in different regions of Iran and BLV-FLK strain were cloned in to a pTZ57R/T vector, then insert were digested by BglII and XhoI restriction enzymes and cloned in to pET-28(a) as an expression vector. For the expression of p24 protein, the pET-28(a) recombinant vector was transformed in BL21(DE3) strain of E. coli competent cell and after induction of the protein having been expressed by IPTG, the presence of gag expressed protein was shown in immunoblotting and SDS-PAGE system. With respect to the remarkable frequency of infection to BLV in Iran and the necessity of controlling it through vaccination with recombinant vaccines of gp51, manufacturing and applying the recombinant p24 protein are vital goals in recognition and distinction between infection and responses caused by vaccine.


Subject(s)
Gene Products, gag/genetics , Leukemia Virus, Bovine/genetics , Animals , Base Sequence , Blotting, Western , Cattle , DNA Primers/genetics , DNA, Viral/genetics , Enzootic Bovine Leukosis/immunology , Enzootic Bovine Leukosis/prevention & control , Escherichia coli/genetics , Gene Expression , Gene Products, gag/biosynthesis , Gene Products, gag/isolation & purification , Genes, gag , Leukemia Virus, Bovine/immunology , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Viral Vaccines/genetics
12.
Vaccine ; 25(47): 8036-48, 2007 Nov 19.
Article in English | MEDLINE | ID: mdl-17936444

ABSTRACT

HIV pseudovirion or virus-like particle vaccines represent a promising approach for eliciting humoral and cellular immune responses. Pseudovirions present the envelope glycoprotein complex in its authentic trimeric form, and thus have the potential to generate neutralizing antibodies against relevant virion-associated epitopes that may be lacking in protein subunit vaccines. The development of pseudovirion particles as a viable vaccine approach for progression to clinical testing has been limited by a number of factors, including shedding of particle-associated gp120, practical limitations to large-scale production and purification, and the generation of antibodies against cellular proteins incorporated on the particle surface that confound the analysis of HIV-specific neutralizing antibody responses. Here, we review methods that address each of these challenges, with a focus on production methods for generating non-infectious Gag-Env pseudovirions. Mammalian cell lines that inducibly express HIV Gag and Env can overcome production limitations, and produce pseudovirions that retain gp120 following purification. Baculovirus production systems have the potential to provide higher quantities of particles, but cleavage of gp160 remains a current limitation. Anti-cellular antibody responses can be diminished by adsorption with cell lysates or whole cells. These technical advances should facilitate the further development of pseudovirion vaccine approaches in preclinical testing and future clinical trials.


Subject(s)
AIDS Vaccines/immunology , Gene Products, env/immunology , Gene Products, env/metabolism , Gene Products, gag/immunology , Gene Products, gag/metabolism , HIV-1/immunology , Virion/immunology , AIDS Vaccines/genetics , AIDS Vaccines/metabolism , Animals , Antibodies/immunology , Bioreactors , Cell Line , Cross Reactions/immunology , Gene Products, env/genetics , Gene Products, env/isolation & purification , Gene Products, gag/genetics , Gene Products, gag/isolation & purification , HIV-1/genetics , HIV-1/metabolism , Humans , Microscopy, Immunoelectron , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Spodoptera , Virion/genetics , Virion/metabolism , Virion/ultrastructure
13.
J Virol Methods ; 143(1): 55-64, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17382412

ABSTRACT

Assessment of in vivo viral replication of live attenuated recombinant vesicular stomatitis virus (rVSV) vaccine vector candidates encoding HIV gag requires comprehensive preclinical safety studies, and development of sensitive assays to monitor the outcome of vaccination of animals is important. In this study, two 2-step quantitative real-time RT-PCR assays were developed; a singleplex assay to detect VSV genomic RNA from ferrets inoculated intra-cranially (IC) or intra-nasally (IN) with either a wild-type (wt) virus or an attenuated rVSV vector engineered to express HIV gag protein, and a duplex assay to simultaneously detect VSV-N and HIV-gag mRNAs from cynomolgus macaques inoculated intra-thalamically (IT) with the same viruses. Using synthetic oligonucleotides as standards, the lower limit of detection of VSV-N and HIV-gag was 50 copies. Results showed high levels of wt VSV(IN) genomic RNA and mRNA in ferret and macaque tissues, respectively, and significantly lower levels of VSV genomic RNA and VSV-N and HIV-gag mRNAs in tissues from animals inoculated with the attenuated rVSV vector. These assays correlated with both the course of infection for these animals, and the infectious viral load measured by a standard plaque assay, and could be used to determine the safety profile of rVSV vaccine vectors.


Subject(s)
AIDS Vaccines , Gene Products, gag/isolation & purification , HIV/genetics , RNA, Viral/isolation & purification , Vesicular stomatitis Indiana virus/genetics , AIDS Vaccines/genetics , Animals , Antiretroviral Therapy, Highly Active , Ferrets , Gene Products, gag/genetics , Genetic Vectors , Macaca , RNA, Viral/genetics , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and Specificity , Vesicular stomatitis Indiana virus/isolation & purification , Viral Load , Virus Replication
15.
J Clin Microbiol ; 44(3): 916-22, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16517876

ABSTRACT

A novel diagnostic test for feline leukemia virus (FeLV) RNA in saliva from naturally infected cats is described in this study. We evaluated different diagnostic tests and compared them with the widely used enzyme-linked immunosorbent assay (ELISA) for the detection of p27 in the diagnosis of FeLV. Blood samples from 445 cats were tested for the presence of provirus by real-time PCR and plasma and saliva specimens from those cats were tested for the presence of viral RNA by real-time reverse transcription (RT)-PCR and for the presence of p27 by ELISA. In comparison to conventional ELISA, the diagnostic sensitivity and specificity of the detection of salivary FeLV RNA by real-time RT-PCR were found to be 98.1 and 99.2%, respectively. Detection of viral RNA in saliva had a positive predictive value of 94.6% and a negative predictive value of 99.7%. The kappa value was 0.96, demonstrating an almost perfect agreement between both tests. Furthermore, we confirmed previous results showing that a number of cats which tested negative for the presence of p27 in plasma were in fact positive for the presence of DNA provirus in blood specimens (5.4%). However, 96.4% of these latently infected cats did not shed viral RNA in saliva; therefore, we assume that these cats are of relatively low clinical importance at the time of testing. This study shows considerable diagnostic value of the detection of saliva FeLV RNA in naturally infected cats. This new diagnostic method has advantages over the conventional ELISA, such as less invasive sample collection and no requirement for trained personnel.


Subject(s)
Leukemia Virus, Feline/genetics , Leukemia Virus, Feline/isolation & purification , Leukemia, Feline/diagnosis , Leukemia, Feline/virology , RNA, Viral/genetics , RNA, Viral/isolation & purification , Reverse Transcriptase Polymerase Chain Reaction/methods , Saliva/virology , Animals , Cats , Cross-Sectional Studies , Enzyme-Linked Immunosorbent Assay/methods , Enzyme-Linked Immunosorbent Assay/statistics & numerical data , Female , Gene Products, gag/blood , Gene Products, gag/isolation & purification , Male , Proviruses/genetics , Proviruses/isolation & purification , Retroviridae Proteins/blood , Retroviridae Proteins/isolation & purification , Reverse Transcriptase Polymerase Chain Reaction/statistics & numerical data , Sensitivity and Specificity , Switzerland
16.
Protein Expr Purif ; 36(2): 312-7, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15249055

ABSTRACT

A cDNA encoding the Simian immunodeficiency virus type (SIV(mac)) Gag capsid protein was introduced into Solanum tuberosum cells by Agrobacterium tumefaciens-mediated transformation methods. The gag gene was detected in the genomic DNA of transformed leaf tissues by PCR DNA amplification. Immunoblot analysis of transformed potato plant extracts with anti-Gag monoclonal antibody showed that biologically active Gag protein was synthesized in transformed tuber tissues. Based on ELISA results, recombinant Gag protein made up 0.006-0.014% of total soluble tuber protein. The synthesis of SIV Gag in transformed potato tubers opens the way for development of Gag-based edible plant vaccines for protection against SIV and potentially HIV-1 infection.


Subject(s)
AIDS Vaccines/isolation & purification , Capsid Proteins/isolation & purification , Gene Products, gag/isolation & purification , HIV Infections/prevention & control , SAIDS Vaccines/isolation & purification , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus/genetics , AIDS Vaccines/genetics , Agrobacterium tumefaciens/genetics , Capsid Proteins/genetics , Gene Expression , Gene Products, gag/genetics , Humans , SAIDS Vaccines/genetics , Solanum tuberosum/genetics
17.
Virology ; 324(1): 204-12, 2004 Jun 20.
Article in English | MEDLINE | ID: mdl-15183067

ABSTRACT

The Mason-Pfizer monkey virus (M-PMV) Gag protein, precursor to the structural proteins of the infectious virion, assembles into immature capsid-like particles when expressed at high levels in bacterial cells. Similar capsid-like particles can be obtained by in vitro assembly using a high concentration of isolated Gag. M-PMV Gag contains a p12 protein that has no corresponding analogues in most other retroviruses and has been suggested to contain an internal scaffold domain (ISD). We have expressed and purified p12 and the N- and C-terminal halves (Np12 and Cp12) that are predicted to be structurally independent domains. The behavior of these proteins was analyzed using chemical cross-linking, CD spectroscopy, and electron microscopy. The N-terminal half of p12 is largely alpha-helical although the C-terminal portion lacks any apparent ordered structure. Both p12 and Np12 form high-order oligomers in vitro and when expressed in E. coli produce organized structures that are visible by electron microscopy. Interestingly, Cp12, as well as the whole protein, can form dimers in the presence of SDS. The data show that both domains of p12 contribute to its ability to multimerize with much of this potential residing in its N-terminal part, most probably within the leucine zipper-like (LZL) sequence.


Subject(s)
Gene Products, gag/isolation & purification , Amino Acid Sequence , Dimerization , Escherichia coli/genetics , Gene Products, gag/chemistry , Leucine Zippers , Molecular Sequence Data , Recombinant Proteins/isolation & purification , Sequence Alignment
18.
Brain Pathol ; 13(2): 144-54, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12744468

ABSTRACT

In HIV-1 encephalitis, HIV-1 replicates predominantly in macrophages and microglia. Astrocytes also carry HIV-1, but the infection of oligodendrocytes and neurons is debated. In this study we examined the presence of HIV-1 DNA in different brain cell types in 6 paraffin embedded, archival post-mortem pediatric and adult brain tissues with HIV-1 encephalitis by Laser Capture Microdissection (LCM). Sections from frontal cortex and basal ganglia were stained by immunohistochemistry for CD68 (microglia), GFAP (astrocytes), MAP2 (neurons), and p24 (HIV-1 positive cells) and different cell types were microdissected by LCM. Individual cells or pools of same type of cells were lysed, the cell lysates were subjected to PCR using HIV-1 gag SK38/SK39 primers, and presence of HIV-1 DNA was confirmed by Southern blotting. HIV-1 gag DNA was consistently detected by this procedure in the frontal cortex and basal ganglia in 1 to 20 p24 HIV-1 capsid positive cells, and in pools of 50 to 100 microglia/macrophage cells, 100 to 200 astrocytes, and 100 to 200 neurons in HIV-1 positive cases but not in HIV-1 negative controls. These findings suggest that in addition to microglia, the infection of astrocytes and neurons by HIV-1 may contribute to the development of HIV-1 disease in the brain.


Subject(s)
Basal Ganglia/virology , Encephalitis, Viral/virology , Frontal Lobe/virology , HIV Core Protein p24/isolation & purification , HIV Infections/pathology , Adolescent , Adult , Aged , Astrocytes/pathology , Astrocytes/virology , Basal Ganglia/pathology , Child , DNA, Viral/analysis , Encephalitis, Viral/pathology , Frontal Lobe/pathology , Gene Products, gag/genetics , Gene Products, gag/isolation & purification , HIV Infections/virology , HIV-1/genetics , HIV-1/isolation & purification , Humans , Macrophages/pathology , Macrophages/virology , Microglia/pathology , Microglia/virology , Micromanipulation/methods , Microscopy, Confocal , Middle Aged , Neurons/pathology , Neurons/virology
19.
J Virol ; 76(11): 5315-25, 2002 Jun.
Article in English | MEDLINE | ID: mdl-11991960

ABSTRACT

Human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) particles typically contain small amounts of the surface envelope protein (SU), and this is widely believed to be due to shedding of SU from mature virions. We purified proteins from HIV-1 and SIV isolates using procedures which allow quantitative measurements of viral protein content and determination of the ratios of gag- and env-encoded proteins in virions. All of the HIV-1 and most of the SIV isolates examined contained low levels of envelope proteins, with Gag:Env ratios of approximately 60:1. Based on an estimate of 1,200 to 2,500 Gag molecules per virion, this corresponds to an average of between 21 and 42 SU molecules, or between 7 and 14 trimers, per particle. In contrast, some SIV isolates contained levels of SU at least 10-fold greater than SU from HIV-1 isolates. Quantification of relative amounts of SU and transmembrane envelope protein (TM) provides a means to assess the impact of SU shedding on virion SU content, since such shedding would be expected to result in a molar excess of TM over SU on virions that had shed SU. With one exception, viruses with sufficient SU and TM to allow quantification were found to have approximately equivalent molar amounts of SU and TM. The quantity of SU associated with virions and the SU:TM ratios were not significantly changed during multiple freeze-thaw cycles or purification through sucrose gradients. Exposure of purified HIV-1 and SIV to temperatures of 55 degrees C or greater for 1 h resulted in loss of most of the SU from the virus but retention of TM. Incubation of purified virus with soluble CD4 at 37 degrees C resulted in no appreciable loss of SU from either SIV or HIV-1. These results indicate that the association of SU and TM on the purified virions studied is quite stable. These findings suggest that incorporation of SU-TM complexes into the viral membrane may be the primary factor determining the quantity of SU associated with SIV and HIV-1 virions, rather than shedding of SU from mature virions.


Subject(s)
HIV Envelope Protein gp120/metabolism , HIV Envelope Protein gp41/metabolism , HIV-1/metabolism , Membrane Glycoproteins/metabolism , Retroviridae Proteins/metabolism , Simian Immunodeficiency Virus/metabolism , Viral Envelope Proteins/metabolism , Animals , CD4 Antigens/metabolism , CHO Cells , Cricetinae , Freezing , Gene Products, env/isolation & purification , Gene Products, env/metabolism , Gene Products, gag/isolation & purification , Gene Products, gag/metabolism , HIV Envelope Protein gp120/isolation & purification , HIV-1/isolation & purification , Heating , Humans , Simian Immunodeficiency Virus/isolation & purification
20.
Protein Expr Purif ; 21(3): 378-85, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11281711

ABSTRACT

A simple and efficient method for expression in Escherichia coli and purification of matrix protein, p17, of human immunodeficiency virus type 1 (HIV-1) of both B- and C-subtypes is described. DNA sequences encoding p17 of B- and C-subtype were cloned from respective gag sequences. The gag sequences were obtained by PCR amplification using DNA extracted from peripheral blood lymphocytes of an HIV-1 infected patient from India. A T7-promoter-based expression system was optimized for expression of p17 in soluble form. p17 (B- and C-subtype) was purified to near homogeneity using conventional chromatographic techniques. Purification of p17 (C-subtype) is described for the first time with yield of 7.7 mg from a 1-liter culture. The yield of p17 (B-subtype) is 14.7 mg from a 1-liter culture, which is severalfold better than that reported earlier. N-terminal sequencing and CD spectra of the purified proteins, p17B and p17C, show that the proteins are properly processed and well-folded. The immunoreactivity of both types of p17 to sera from HIV-infected individuals is comparable.


Subject(s)
Gene Products, gag/genetics , Gene Products, gag/isolation & purification , HIV Antigens/genetics , HIV Antigens/isolation & purification , HIV Infections/virology , HIV-1/classification , HIV-1/genetics , Viral Proteins , Amino Acid Sequence , Circular Dichroism , Cloning, Molecular , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Escherichia coli/genetics , Gene Products, gag/chemistry , Gene Products, gag/immunology , Genetic Vectors , HIV Antigens/chemistry , HIV Antigens/immunology , HIV Infections/immunology , HIV-1/chemistry , HIV-1/immunology , Humans , Immune Sera/immunology , India , Molecular Sequence Data , Protein Structure, Secondary , gag Gene Products, Human Immunodeficiency Virus
SELECTION OF CITATIONS
SEARCH DETAIL
...